Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(25%)

Phase Distribution

Ph phase_2
1
25%
Ph phase_1
3
75%

Phase Distribution

3

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
3(75.0%)
Phase 2Efficacy & side effects
1(25.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(2)
Terminated(1)
Other(1)

Detailed Status

Completed2
Terminated1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
66.7%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (75.0%)
Phase 21 (25.0%)

Trials by Status

terminated125%
unknown125%
completed250%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_2

Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia

NCT00005962
terminatedphase_1

Liposomal Daunorubicin in Treating Patients With HIV-Related Kaposi's Sarcoma

NCT00427414
unknownphase_1

Liposomal Daunorubicin in Treating Patients With Metastatic Breast Cancer

NCT00004207
completedphase_1

Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial Therapy

NCT00005942

Clinical Trials (4)

Showing 4 of 4 trials
NCT00005962Phase 2

Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia

Completed
NCT00427414Phase 1

Liposomal Daunorubicin in Treating Patients With HIV-Related Kaposi's Sarcoma

Terminated
NCT00004207Phase 1

Liposomal Daunorubicin in Treating Patients With Metastatic Breast Cancer

Unknown
NCT00005942Phase 1

Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial Therapy

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4